###### Summary box

What is already known about this subject?
=========================================

1.  Bowel movements (BM) is perhaps the least understood and less studied of all human bodily functions.

2.  BM with less than three movements a week is considered as constipation, and more than three watery stools a day as diarrhoea.

3.  However, non-diarrhoeal increased frequency of BM (IFoBM-ND) in children has not been considered as a clinical symptom associated with viral infections.

What are the new findings?
==========================

1.  This follow-up study of a cohort from birth up to 2 years of age reveals for the first time that non-polio enterovirus (NPEV) infections are associated with acute and persistent IFoBM-ND in children.

2.  NPEV-IFoBM-ND accounted for about 29% of NPEV infection episodes and 83% of total IFoBM-ND episodes.

3.  NPEV infections appear to result in resolution of about 74% of constipation episodes.

How might it impact on clinical practice in the foreseeable future?
===================================================================

1.  The present finding of NPEV association with IFoBM in children, including acute and persistent IFoBM-ND and diarrhoea, could impact on future clinical understanding of IFoBM-ND and its recognition as a gastrointestinal disease symptom in clinical practice, and promote active research towards antienteroviral therapeutics.

Background {#s1}
==========

The frequency of bowel movements (BM) refers to the number of times a person discharges stool from the large intestine each day. There is no general rule for normal frequency of BM, which varies from three times a day to three times a week, and from person to person. However, it is commonly considered that a great majority of people have one BM each day.[@R1] A variety of conditions may cause a significant increase in the frequency of BM, which include bacterial, parasitic or viral infections of the gastrointestinal tract, coeliac disease, cancer of the digestive tract, food allergies, diverticulitis, gall bladder disease or stones, lactose intolerance, inflammatory bowel disease (Crohn\'s disease and ulcerative colitis), irritable bowel syndrome (IBS), certain medications or drug overdose, etc.[@R6] Increased frequency of BM can be either diarrhoeal, referred to as IFoBM-D, or non-diarrhoeal (IFoBM-ND). Frequent BM can be associated with a serious disease such as bowel obstruction and pancreatitis leading to a life-threatening condition. Other digestive as well as non-digestive symptoms including abdominal pain or cramping, bloody stool, diarrhoea, faecal incontinence, gas, abdominal swelling or bloating, nausea with or without vomiting, painful BM, urgent need to pass stool, body aches and fever might occur along with frequent BM.[@R2]

The majority of studies on the frequency of BM are based either on data recorded in sets of children of different age groups,[@R5] [@R12] or on the recording of BM only at specific months after birth[@R15] or information provided by parents of children of specific age to a bowel-habit questionnaire.[@R16] [@R17] Further, significant differences in BM frequency appear to exist between children in developed and developing countries due to ethnic differences in dietary factors.[@R4] Most of these studies suffer from severe variation in design and validity, and are only moderately sensitive.[@R18] To the best of our knowledge, there is no systematic follow-up study on a day-to-day basis on frequency and type of BM, both IFoBM-D and IFoBM-ND, and analysis of the causes for change in BM frequency in a cohort of children from birth to 2 years of age.

The genus enterovirus (EV), belonging to the family Picornaviridae, consists of a large group of viruses[@R19] [@R20] that are associated with a wide variety of diseases in humans including acute flaccid paralysis, aseptic meningitis, encephalitis, type-1 diabetes, hand-foot-and-mouth disease, uveitis, cardiomyopathy, aplastic anaemia, coagulopathy, multisystem haemorrhagic disease, sudden deafness, fatal illness with pulmonary hypertension in neonates, diarrhoea, etc.[@R19] Poliovirus, coxsackievirus (CVA and CVB), echovirus (E), newer EVs and rhinovirus represent major pathogenic species of humans in the EV genus, and together present about 200 serotypes.[@R19] [@R20]

A recent long-term epidemiological study in Bangalore, India, from our laboratory revealed a significant association of non-polio EVs (NPEVs) with acute diarrhoea in children.[@R23] Further, a follow-up of 140 infants from birth for 6 months to 2 years of age revealed significant association of NPEV infections with acute diarrhoea as well as persistent diarrhoea (PD).[@R30]

During the large-scale purification of an echovirus 19 (E19) strain isolated from a child suffering from PD, called the persistent diarrhoea-associated virus (PDV; GenBank Accession number JX513514) for antibody generation, DCR had accidental infection resulting in a symptom, referred to as 'non-diarrhoeal persistent IFoBM' (PIFoBM-ND), which lasted for about 3 months. This symptom is often characterised by intense BM, an urgency to pass apparently normal stools more than twice a day instead of the normal once a day, abdominal bloating and discomfiture. This infection also resulted in a mild loss of motor function of the right hand, leading to stammering and incoherent handwriting. PDV was detected in the stools for more than 2 months, followed by E6 strain for about 12 days. The symptom subsided after a final mild diarrhoeal episode involving an enteropathogenic *Escherichia coli* infection for 3 days. Although IFoBM-ND shares some symptoms associated with IBS[@R2] [@R31] such as urgency for BM, discomfort, a feeling of incomplete evacuation (tenesmus) and abdominal bloating, as was experienced by DCR,[@R30] comorbidities such as chronic abdominal pain, diarrhoea or constipation, headache, backache, fibromyalgia, chronic fatigue syndrome or psychiatric symptoms such as depression and anxiety frequently associated with IBS[@R31] were not observed.

This unusual clinical symptom prompted us to undertake the present follow-up study of a cohort of infants from birth up to 2 years of age to understand the frequency of NPEV infections and their associated clinical outcomes including diarrhoea and IFoBM-ND. In a recent report, we described the frequency of NPEV infections, and association of 18% of the NPEV infection episodes with diarrhoea (12% acute and 6% persistent) in this cohort.[@R23] We present an analysis of the apparently asymptomatic (referred to as non-diarrhoeal in our recent report[@R23]) NPEV infection episodes and their association with IFoBM-ND as observed in the cohort in the community setting.

Methods {#s2}
=======

Definitions {#s2a}
-----------

BM or bowel habit is referred to as discharge or passing of stool from the large intestine, or defaecation. Frequency of BM is the number of times an individual passes stools each day. BM ranges from three times a day to three times a week among different individuals. Less than three movements a week is considered as constipation[@R34] and more than three watery stools a day is considered as diarrhoea.[@R1] [@R2] In this study, passing more than three apparently normal stools in a day or twice that of the existing frequency is considered as IFoBM-ND, the majority of acute IFoBM-ND (AIFoBM-ND) episodes lasting for less than 7 days and a few extending up to 14 days, and PIFoBM-ND episodes lasting for more than 14 days and up to three or more months. The corresponding IFoBM episodes involving watery stools are similarly considered as acute diarrhoea (AIFoBM-D) and PD (PIFoBM-D).[@R35] [@R36]

The cohort {#s2b}
----------

The cohort, consisting of 140 infants, was recruited from birth over a period of 24 months between 2009 and 2010. All infants were normal and healthy at birth and remained normal during the study period. The major criteria for selection are the willingness of the parents to participate in the long-term study, and that they do not move out of the city during the study period. The mother was trained to carefully monitor and record the number and type of stools (diarrhoeal and non-diarrhoeal) daily, and to collect a stool sample in a sterile container on the designated date. The children were located within a radius of 6 km and the mothers were accessible by phone. R. M. V. Hospital, M. S. Ramaiah Teaching Hospital, Agadi Hospital and Arpita Clinic served as nodal centres for the 2-year follow-up study. More details on the cohort are described recently.[@R23] [@R30]

Stool samples {#s2c}
-------------

Stool samples were collected once in 14 days, and on alternate days during a diarrhoeal episode or an infection episode identified by NPEV or rotavirus (RV) positivity.[@R23] [@R30] The samples were transported from the residences of children to the laboratory on ice the same day.

Oral polio vaccine period {#s2d}
-------------------------

Almost every child in India receives oral polio vaccine (OPV) six to seven times during the first 2 years of life. Although a majority of OPV recipients shed vaccine strains for less than 7 days, a significant number of children were found to shed the virus up to 14 days and a few beyond 14 days.[@R22] [@R23] [@R30] Hence, the clinical protocol should distinguish samples positive for OPV strains to reduce the burden of sequencing them from the large number of samples, which become EV positive in cell culture and reverse transcription PCR (RT-PCR). The 14-day period following OPV administration is referred to as the OPV period, and the majority of the samples positive for virus growth in rhabdomyosarcoma or HeLa cells, except the 100 random samples collected during this period, are considered OPV positive and are not subjected to RT-PCR and sequence analysis. However, all strains positive in the diarrhoea samples were identified by sequencing the VP1 gene.[@R22] [@R23] [@R30]

Identification of EV, RV and other agents in stool samples {#s2e}
----------------------------------------------------------

Methods for detection of NPEVs and other picornaviruses (kobuvirus, classevirus and cardiovirus), RV, diarrhoeagenic *E. coli* were described previously.[@R22] [@R23] [@R30] The serotypes of NPEVs were identified by comparison of complete VP1 gene sequences with the prototype and other NPEV sequences in the GenBank database using the BLAST programme and by phylogenetic analysis.[@R22] [@R23] [@R30] [@R37] Nucleotide sequencing was carried out at Macrogen (Korea).

Ethics {#s2f}
------

Approvals from the Institutional Biosafety Committee and Ethical Committee were obtained for carrying out the work.

Statistical analysis {#s2g}
--------------------

The data in Microsoft Office Excel format were subjected to statistical analyses using the Fisher exact test, the student t-test and computed p values as described.[@R30] [@R38]

Results {#s3}
=======

Age-dependent frequency of BM {#s3a}
-----------------------------

Owing to unexpected dropouts, the follow-up period for different children varied from 6 months to 2 years.[@R30] For convenience, the study duration was divided into four periods of 6 months each. Analysis of the frequency of passing of stools and type of stools (diarrhoeal and normal) in the cohort recorded daily during the follow-up period revealed that the frequency of BM ranged between 0 and 16 during the first 6 months of life, between 0 and 12 during the 7--12-month period, between 0 and 8 for the 13--18-month period and between 0 and 4 during the 19--24-month period. The mean frequency among the cohort children for the four successive 6-month periods was 3.3, 1.6, 1.2 and 0.98, respectively ([figure 1](#BMJGAST2014000011F1){ref-type="fig"}). Although the daily frequency of BM in a majority of the children ranged between 1 and 3, some infants passed stools once in 2--4 days or 5--10 days on more than one occasion ([figure 2](#BMJGAST2014000011F2){ref-type="fig"}). Very few infants had 1 BM/day (\<4% of total BM) during the first 6-month period, but the number of children having 1 BM/day increased with age with \>92% having passing 1 BM/day by 2 years of age. The frequency of BM is high in all children below 6 months of age with 2, 3--4 and 5--16 BM/day representing 15%, 23% and 34%, respectively. Of note, while about 7% and 17% of the non-diarrhoeal BM occurred once in 2--4 days and 5--10 days, respectively, in children below 6 months of age, this category of BM represented less than 1--2% in children older than 6 months. The frequency of BM ranged between 0 and 16/day among the children in all age groups. Approximately 87% of IFoBM-ND episodes occurred during the first year with \>57% occurring during the first 6 months. While about 82% and 10% of children in the age group of 12--18 months had 1 and 1--2 BM/day, respectively, about 97% of children in the age group of 19--24 months had only 1 BM/day. It should be noted that as a tradition, almost every infant in India is trained to pass stools every day in the morning by the time the child reaches 1--2 years of age.

![Age-dependent average frequency of non-diarrhoeal bowel movements (BM-ND) in the cohort. The 2-year follow-up duration is divided for convenience into four 6-month periods. The frequency of non-diarrhoeal BM per day during the four successive 6-month periods from birth ranged between 0--16, 0--12, 0--8 and 0--4, respectively.](bmjgast2014000011f01){#BMJGAST2014000011F1}

![Age-dependent changes in bowel movement (BM) frequencies. BM frequencies were grouped into six categories, 1 in a day (1/D), 2 in a day (2/D), 3--4 in a day (3--4/D), 5--17 in a day, 1 in 2--4 days (1/2--4D) and 1 in 5--10 days (1/5--10D). The per cent proportion of non-diarrhoeal BM of each category in each age group is calculated with reference to the total number of non-diarrhoeal BM of the respective category occurring in all the four age groups.](bmjgast2014000011f02){#BMJGAST2014000011F2}

EV association with IFoBM-ND {#s3b}
----------------------------

Since DCR experienced PIFoBM-ND for about 3 months following accidental infection with the E19 strain, PDV, isolated from a child with PD, the cohort children were carefully monitored each day for the frequency of passing of stools. The stool samples were examined for the presence of NPEVs, and the data were analysed for correlation between changes in frequency of BM and NPEV infection. Of 403 NPEV infection episodes observed among the 140 children during the follow-up period,[@R23] [@R30] 115 were IFoBM-ND episodes. Further, 24 IFoBM-ND episodes that were negative for NPEV infection were also observed. Thus while NPEV-positive and NPEV-negative IFoBM-ND episodes represented 83% (115/139) and 17% (24/139) of total IFoBM episodes, respectively, the former accounted for 28.5% (115/403) of total NPEV infection episodes ([table 1](#BMJGAST2014000011TB1){ref-type="table"}). The NPEV-negative IFoBM-ND episodes were all acute and represented about 17% of the episodes ([table 1](#BMJGAST2014000011TB1){ref-type="table"}).

###### 

Analysis of IFoBM-ND episodes in comparison to diarrhoeal episodes

                                                           Subjects, samples, episodes                                 0--6 months      6--12 months    12--18 months   18--24 months    Total (%)
  -------------------------------------------------------- ----------------------------------------------------------- ---------------- --------------- --------------- ---------------- ------------------
  1                                                        Cohort children followed (n=140)                            140              130             112             70               140
  2                                                        Total samples                                               1724             1603            1381            864              5572
  3                                                        Total OPV-negative samples                                  1078             1430            1268            769              4545
  4                                                        Total NPEV-positive samples                                 260              179             135             84               638/4545 (14.0)
  5                                                        Total NPEV-negative samples                                 818              1251            1133            685              3907/4545 (86.0)
  6                                                        Total NPEV episodes                                         162              115             76              50               403/4545 (8.9)
  7                                                        NPEV+ve-acute episodes (%)                                  103/162 (63.6)   83/115 (72.2)   49/76 (64.5)    33/50 (66.0)     268/403 (66.5)
  Acute diarrhoeal episodes                                19                                                          13               10              6               48/403 (11.9)    
  NPEV-AIFoBM-ND/total NPEV-IFoBM-ND episodes (%)          25/61 (41.0)                                                21/61 (34.4)     9/61 (14.8)     6/61 (9.8)      61/115 (53.0)    
  NPEV-AIFoBM-ND/total NPEV episodes (%)                   25/162 (15.4)                                               21/115 (18.3)    9/76 (11.8)     6/50 (12.0)     61/403 (15.1)    
  NPEV-acute symptomatic (IFoBM+diarrhoea)                 44                                                          34               19              12              109/403 (27.1)   
  Acute asymptomatic NPEV episodes                         59                                                          49               30              21              159/403 (39.5)   
  8                                                        NPEV-positive persistent episodes                           59               32              27              17               135
  NPEV-positive PD episodes (%)                            7/162 (4.3)                                                 7/115 (6.1)      9/76 (11.8)     2/50) (4.0)     25/403 (6.2)     
  NPEV-PIFoBM-ND/total NPEV-PIFoBM-ND (%)                  26\*/54 (48.2)                                              12/54 (22.2)     9/54 (16.7)     7/54 (13.0)     54/115 (47.0)    
  NPEV-PIFoBM-ND/total NPEV episodes (%)                   26/162 (16.0)                                               12/115 (10.4)    9/76 (11.8)     7/50 (14.0)     54/403 (13.4)    
  NPEV-persistent symptomatic (PD+PIFoBM-ND)               33                                                          19               18              9               79/403 (19.6)    
  Persistent asymptomatic NPEV episodes                    26                                                          13               9               8               56/403 (13.9)    
  9                                                        Non-NPEV-IFoBM-ND episodes                                  15               6               2               1                24/139 (17.3)
  10                                                       NPEV-IFoBM-ND/total NPEV-IFoBM-ND (%)                       51/115 (44.4)    33/115 (28.7)   18/115 (15.6)   13/115 (11.3)    115/403 (28.5)
  NPEV-IFoBM-ND/total NPEV- +non-NPEV-IFoBM-ND (%)         51/139 (36.7)                                               33/139 (23.7)    18/139 (12.9)   13/139 (9.4)    115/139 (82.7)   
  Total NPEV-IFoBM-ND/total non-diarrhoeal episodes (%)    51/330 (15.5)                                               33/330 (10.0)    18/330 (5.5)    13/330 (3.9)    115/330 (34.9)   
  11                                                       NPEV diarrhoeal episodes/NPEV infection episodes (%)        26/162 (16.1)    20/115 (17.4)   19/76 (25.0)    8/50 (16.0)      73/403 (18.0)
  12                                                       NPEV symptomatic episodes/period (%)                        77/162 (47.5)    53/115 (46.1)   37/76 (48.7)    21/50 (42.0)     188/403 (46.7)
  NPEV symptomatic episodes/total NPEV episodes (%)        77/403 (17.0)                                               53/403 (13.2)    37/403 (9.2)    21/403 (5.2)                     
  13                                                       NPEV asymptomatic episodes/period (%)                       85/162 (52.5)    62/115 (53.9)   39/76 (51.3)    29/50 (58.0)     215/403 (53.3)
  NPEV asymptomatic episodes/total NPEV episodes (%)       85/403 (21.1)                                               62/403 (15.4)    39/403 (9.7)    29/40 (6.9)                      
  NPEV asymptomatic episodes/non-diarrhoeal episodes (%)   85/330 (25.8)                                               62/330 (18.8)    39/330 (11.8)   29/330 (8.8)    215/330 (65.2)   
  14                                                       RV diarrhoea/RV episodes (%)                                16/49 (32.7)     14/23 (60.9)    7/15 (46.7)     5/9 (55.6)       42/96 (43.7)
  15                                                       NPEV-RV-positive episodes                                   15               4               4               2                25/4545 (0.5)
  16                                                       NPEV+RV-diarrhoeal episodes/total diarrhoeal episodes (%)   9/193 (4.6)      1 (0.5)         1 (0.5)         1 (0.5)          12/193 (6.2)
  17                                                       Diarrhoea due to other agents/total diarrhoea (%)           25/193 (12.9)    20/193 (10.3)   13/193 (6.7)    8/193 (4.1)      66/193 (34.2)

**\***One PIFoBM-ND episode was of NPEV-RV mixed infection.

Details of diarrhoeal episodes, OPV samples, NPEV-positive and NPEV-negative samples have been described in detail previously.[@R30]

AIFoBM, acute increased frequency of bowel movements; IFoBM-ND, non-diarrhoeal IFoBM; NPEV, non-polio enterovirus; OPV, oral polio vaccine; PD, persistent diarrhoea; PIFoBM-ND, persistent IFoBM-ND; RV, rotavirus.

While acute NPEV infections ranged between 64% and 72%, persistent infections were between 28% and 36% in all the age groups. Among 115 NPEV-positive IFoBM-ND episodes, acute and persistent episodes occurred at similar frequencies (61 acute (53%) and 54 persistent (47%)) with greater than 70% of both types of episodes occurring during the first year of life. AIFoBM-ND episodes accounted for about 15% of the total NPEV infection episodes and PIFoBM-ND episodes accounted for \>13% ([figure 3](#BMJGAST2014000011F3){ref-type="fig"} and [table 1](#BMJGAST2014000011TB1){ref-type="table"}).

![Per cent proportion of different non-polio enterovirus (NPEV)-associated symptoms with reference to total NPEV infection episodes in the cohort community during the 2-year follow-up period. Total number of samples, total NPEV-positive episodes, diarrhoeal episodes and oral polio vaccine samples in the follow-up study were described previously[@R30] (IFoBM, increased frequency of bowel movements).](bmjgast2014000011f03){#BMJGAST2014000011F3}

NPEV serotypes associated with IFoBM-ND {#s3c}
---------------------------------------

We recently identified 24 NPEV serotypes associated with acute diarrhoea and 16 types with PD in this cohort.[@R30] In the present analysis, of the 20 NPEV types detected, only 5 types E1, E6, E11, E19 and E24 were more frequently associated with IFoBM-ND. E6, E11 and E19 were frequently observed to persist for extended periods in PIFoBM-ND episodes, involving monotypic and sequential infections by different serotype strains ([table 2](#BMJGAST2014000011TB2){ref-type="table"}). Note that many of the PIFoBM-ND episodes are repeated against different serotypes in [table 2](#BMJGAST2014000011TB2){ref-type="table"} due to sequential infections involving strains belonging to several NPEV serotypes during many of the episodes.

###### 

NPEV serotypes associated with acute diarrhoea, PD, AIFoBM, PIFoBM and asymptomatic infections, and the sequence of infections in PIFoBM episodes involving EV, RV and DEC

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  EV-serotypes   Strains in acute & PD episodes analysed   Frequency of detection of different NPEV serotypes in 48 independent PIFoBM-ND episodes analysed                                                                                                      AIFoBM-ND episodes analysed   Total IFoBM-ND samples/episodes analysed   Asymptomatic EV episodes analysed   Total EV samples/episodes examined
  -------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ------------------------------------------ ----------------------------------- ------------------------------------
  E1             2                                         *10 (EV83, E1)*, *(E1, 33)*, *(E1, 11), (E32, 1, 2),*\                                                                                                                                                10                            20                                         10                                  32
                                                           *(E7, 33, 1), (E1, 2), (E1, 25), (E11, 1), (E25, 25, 1, 1, 19, EPEC, RV), (E2, 1),*                                                                                                                                                                                                                                

  E2             2                                         *3 (E2, 1), (E32, 1, 2), (E1, 2)*                                                                                                                                                                     --                            3                                          --                                  5

  E3             2+*2*                                     --                                                                                                                                                                                                    1                             1                                          1                                   6

  E5             1                                         --                                                                                                                                                                                                    --                            --                                         --                                  1

  E6             5+*10*                                    *13* (E6, 6, 6), (E6, 6, 6), *(E6, 6, EPEC, RV),*\                                                                                                                                                    3                             16                                         2                                   33
                                                           (E6, 6, 6), (E6, 6, 6, 6), *(E21, 6, 6, OPV1), (E6, 19, 19), (E6, 19)*, *(E6, 19, OPV1), (E11, 11, 6)*, *(E21, 21, 6), (E11, 11, OPV1, 6, EAEC), (E19, 19, 19, 19, RV, E6, ETEC)*                                                                                                                                  

  E7             2+*8*                                     *2 (E7, 33, 1), (E21, 7)*                                                                                                                                                                             2                             4                                          1                                   15

  E11            6+*3*                                     *16* (E11, 11), (E11, 11), (E11, 11, 11, 11),\                                                                                                                                                        6                             22                                         8                                   39
                                                           *(E11, 1), (E11, 11, 24), (E1, 11), (E25, 11*), *(E11, CVA9), (E32, 11), (E11, 11, 6), (E11, 11, OPV1, 6, EAEC), (E11, 11, 24, 24), (E11D, 32, OPV1), (OPV1, E11, 11), (E11D, 32, OPV1), (E11, RV)*                                                                                                                

  E12            --                                        --                                                                                                                                                                                                    --                            --                                         2                                   2

  E13            4+*2*                                     *1* (E13, 13)                                                                                                                                                                                         1                             2                                          1                                   9

  E14            2+*1*                                     *4* (E14, 14), *(E14, 24), (E1, 11, 14), (E14, 19),*                                                                                                                                                  2                             6                                          2                                   11

  E19            3+*3*                                     *6 (E6,19,19)*, *(E6, 19), (E14, 19) (E25, 25, 1, 19, 19, EPEC, RV), (E6, 19, RV, OPV1), (E19, 19, 19, 19, RV, E6, ETEC)*                                                                             3                             9                                          5                                   20

  E20            2                                         *2* (E20, 20), *(E20, 33)*                                                                                                                                                                            2                             4                                          3                                   9

  E21            --                                        *3*(E21, 21), *(E21, 6, 6, OPV1)*, *(E21, 21, 6)*                                                                                                                                                     1                             4                                          2                                   6

  E24            3+*3*                                     *6* (E24, 24), *(E24, 32), (E24, 32), (E11, 11, 24), (E14, 24), (E11, 11, 24, 24)*                                                                                                                    2                             8                                          1                                   15

  E25            --                                        *3(E25, 25, 1, 1, 19, EPEC, RV), (E1, 25), (E25, 11)*                                                                                                                                                 2                             5                                          2                                   7

  E30            1                                         --                                                                                                                                                                                                    --                            --                                         2                                   3

  E32            1+*1*                                     *4 (E32, 11), (E24, 32), (E32, 1, 2) (E11, 32, OPV1)*                                                                                                                                                 2                             6                                          2                                   10

  E33            4+*2*                                     *3 (E7, 33, 1),* (*E1, 33), (E20, 33)*                                                                                                                                                                3                             6                                          2                                   14

  EV75           3+*2*                                     --                                                                                                                                                                                                    --                            --                                         --                                  5

  EV76           --                                        --                                                                                                                                                                                                    --                            --                                         1                                   1

  EV83           --                                        *1 (EV83, E1)*                                                                                                                                                                                        1                             2                                          1                                   3

  CVA4           1+*1*                                     --                                                                                                                                                                                                    --                            --                                         1                                   3

  CVA9           1+*1*                                     --                                                                                                                                                                                                    1                             1                                          1                                   4

  CVA13          1                                         --                                                                                                                                                                                                    --                            --                                         1                                   2

  CVA24          1+*1*                                     --                                                                                                                                                                                                    1                             1                                          --                                  3

  CVB3           2                                         --                                                                                                                                                                                                    1                             1                                          1                                   4

  CVB4           1+*2*                                                                                                                                                                                                                                           1                             1                                          1                                   5

  CVB5           1+1                                       --                                                                                                                                                                                                    --                            --                                         --                                  2

  OPV1           1+*2*                                     *4 (OPV1, E11, 11), (E21, 6, 6, OPV1), (E11D, 32, OPV1), (E6, 19, OPV1)*                                                                                                                              --                            4                                          --                                  7

  OPV2           1                                         --                                                                                                                                                                                                    --                            --                                         --                                  1

  OPV3           1                                         --                                                                                                                                                                                                    --                            --                                         --                                  1

  Total          54+*45 =99* (80)                          *81 (12 mono+69 sequential)* (48)                                                                                                                                                                     45                            *126* (91)                                 53                                  *278* (222)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The numbers in each row in each column represent the number of episodes from which the VP1 gene from strains belonging to the particular EV serotype was sequenced. Strains indicated in parenthesis in italic font refer to sequential infections by more than one NPEV serotype or agent in that order and those in normal font refer to monotypic infections. Strains from all the IFoBM-ND and asymptomatic NPEV infection episodes were not examined. Numbers in italic font in the bottom row include some sequentially collected samples during persistent episodes indicating representation of some episodes more than once, and the numbers in parenthesis in normal font in the bottom row indicate actual number of PIFoBM-ND episodes analysed. In the second column, numbers in normal and italic fonts represent samples from acute and persistent diarrhoeal episodes, respectively.

AIFoBM, acute increased frequency of bowel movements; CVA, coxsackievirus A; CVB, coxsackievirus B; DEC, diarrhoeagenic *Escherichia coli;* E, echovirus; EAEC, enteroaggregative *E. coli;* EPEC, enteropathogenic *E. coli*; ETEC, enterotoxigenic *E. coli*; EV, enterovirus; IFoBM-ND, non-diarrhoeal IFoBM; NPEV, non-polio enterovirus; OPV, oral polio vaccine; PD, persistent diarrhoea; PIFoBM, persistent IFoBM; RV, rotavirus.

Comparative analysis of diarrhoeal and IFoBM-ND episodes {#s3d}
--------------------------------------------------------

Analysis of IFoBM-ND and diarrhoeal episodes revealed that while diarrhoeal episodes accounted for 18%,[@R30] IFoBM-ND accounted for about 29% (115/403) of the NPEV infection episodes. Thus, a significantly greater number of NPEV infections is associated with IFoBM-ND than with diarrhoea. While NPEV-associated diarrhoeal episodes accounted for about 38% (73/193), and RV-associated diarrhoea for 22% (42/193), those due to other agents represented about 34% (66/193) of the total diarrhoeal episodes ([table 1](#BMJGAST2014000011TB1){ref-type="table"}).[@R30] Taking into consideration our recent observation that about18--21% of diarrhoeal cases reporting to paediatricians are NPEV positive,[@R23] about half of the NPEV-associated diarrhoeal episodes occurring in the community appear to remain unreported in India.[@R23] [@R30]

In our recent analysis of diarrhoeal episodes in the cohort, prior to analysis of IFoBM-ND symptoms, all NPEV infection episodes of IFoBM not associated with diarrhoea were considered as non-diarrhoeal or asymptomatic.[@R30] Analysis revealed that about 35% (115/330) of the apparently asymptomatic NPEV infection episodes and 29% (115/403) of the total NPEV infection episodes were associated with IFoBM-ND symptoms. Thus, NPEV symptomatic infections (diarrhoea (18--21%)[@R23] [@R30] and IFoBM-ND (29%)), excluding NPEV-RV-positive mixed diarrhoeal infections, accounted for about 50% of total NPEV-positive infection episodes.

Of interest, among the three highly prevalent NPEV serotypes (EV1, EV6 and EV11) associated with IFoBM-ND, E6 and E11 types were also frequently detected in diarrhoeal samples, but E1 is rarely associated with diarrhoea. Many serotypes were associated with symptomatic infections (diarrhoea and IFoBM-ND) and asymptomatic infections. While EV serotypes E21, E25 and EV83 were detected only in IFoBM-ND and asymptomatic infections, E5, EV75 and CVB5 were detected only in diarrhoeal samples[@R30] ([table 2](#BMJGAST2014000011TB2){ref-type="table"}).

Similar to that observed in PD episodes,[@R30] PIFoBM-ND episodes were characterised either by persistence of a single strain for a prolonged period or sequential infection by multiple strains during the persistent episode ([table 2](#BMJGAST2014000011TB2){ref-type="table"}). While all AIFoBM-ND episodes involved monotype infections ([table 2](#BMJGAST2014000011TB2){ref-type="table"}), 25% of PIFoBM-ND episodes were of monotype infections and 75% involved sequential infections by different strains. However, both types of infections occurred at a similar frequency in PD episodes.[@R30] Among the agents examined, OPV strains, RV and diarrhoeagenic *E. coli* were detected in a small number of samples from a few episodes. When diarrhoeagenic *E. coli* was detected during some NPEV infection episodes, the stool was loose, but not diarrhoeal.

Discussion {#s4}
==========

Among all bodily functions, BM is the most poorly studied and least understood. Although infectious and non-infectious causes may be associated with IFoBM, bacterial, parasitic and viral infections are frequently associated with diarrhoea (IFoBM-D).[@R1] [@R2] [@R23] [@R34] To date, neither IFoBM-ND has been recognised as a clinical symptom nor a viral agent has been implicated to be associated with it. The present novel clinical finding of significant association of NPEV infection with IFoBM-ND in children strongly supports the personal experience and inconvenience suffered by DCR with the clinical symptom.

This study represents the first description of a possible viral aetiology of IFoBM-ND, both AIFoBM-ND and PIFoBM-ND, in infants and children. NPEV-associated IFoBM-ND episodes accounted for about 29% of NPEV infection episodes and 83% of total IFoBM-ND episodes ([table 1](#BMJGAST2014000011TB1){ref-type="table"}). In about 17% of IFoBM-ND episodes, no NPEV or other examined agents were detected, suggesting the association of non-infectious causes or unknown agents with these episodes.

Of interest, 26 infants, included in the total number of NPEV-associated IFoBM-ND episodes, with a BM frequency of one in 4--10 days, had one or two normal stools per day following NPEV infection. However, no change in BM frequency was observed in nine children with constipation on NPEV infection. Thus, while about 74% of constipation episodes[@R34] appear to have been resolved following NPEV infection, no effect was observed in 26% of constipation episodes on NPEV infection. To date, the clinical basis of constipation and their subsequent resolution in infants is poorly understood. The lack of change in BM frequency in these episodes could be due to the genetic diversity of the infecting NPEV isolates.

Recently, we reported a significant association of NPEV infections with acute diarrhoea as well as PD, and that every child in this cohort had at least one NPEV infection, symptomatic (diarrhoeal) and/or asymptomatic, by 2 years of age.[@R23] [@R30] Analysis of NPEV strains associated with IFoBM-ND episodes in the present study revealed the patterns of NPEV association with AIFoBM-ND and PIFoBM-ND episodes to be similar to that observed for PD episodes. While monotype infections were associated with about 25% of PIFoBM-ND episodes, sequential infections by different EV serotype strains were associated with 75% of episodes. By contrast, infection involving monotype strains and multiple strains occurred at a similar frequency in PD episodes.[@R30] OPV strains, RV and/or diarrhoeagenic *E. coli* were detected only in a small number of sequential samples from a few PIFoBM-ND episodes ([table 2](#BMJGAST2014000011TB2){ref-type="table"}). It may be noted that two PIFoBM-ND episodes started as acute diarrhoea involving EV11 infection, but transformed into PIFoBM-ND after 4 days.

Although no child in the cohort developed serious complications during NPEV infection episodes, 20 children had three to four episodes of common cold, 23 had minimal non-febrile illness and 19 had respiratory illness, 80% of which coincided with NPEV infections. These events associated equally with diarrhoeal and non-diarrhoeal NPEV episodes. Twenty-seven babies had non-specific vomiting during the first 3 months without correlation to EV infection. No hand-foot-and-mouth disease or meningitis symptoms were observed in the cohort during this period. All the children were normal and healthy and did not suffer from inflammatory bowel disease, IBS or coeliac disease.

A notable finding was that NPEV is the single most frequently and persistently detected infectious agent in PIFoBM-ND episodes than any other agent we have examined in this study, similar to that observed in PD episodes.[@R30] In this context, EVs are known to cause persistent infections in humans, animal models and cells in vitro with some strains capable of persisting for several months.[@R39] Although it is considered that \<1% of EV infections result in severe disease with the majority being asymptomatic,[@R19] our recent and present results reveal that about 50% of NPEV infections are associated with significant gastrointestinal symptoms involving diarrhoea and IFoBM-ND. Although the precise molecular basis for the symptomatic/asymptomatic nature of the isolates is not understood, mutations in the virus[@R44] and host factors could influence the replication and clinical outcome of the infection.[@R47] Our recent studies showed that Indian isolates exhibit a significant genetic diversity from strains isolated in other countries, forming distinct genogroups or subgenogroups within a genotype.[@R22] [@R23] [@R30] This high level of genetic variation among isolates within a serotype could result in different isolates exhibiting a wide range of virulence phenotypes.

In conclusion, this study revealed (1) an unrecognised but highly significant clinical symptom, IFoBM-ND, in children with possible EV aetiology, (2) a similarity in BM frequency between diarrhoeal and IFoBM-ND episodes in children, the two symptoms differing in the type of stools passed, with the former characterised by watery stools and the latter by apparently normal stools, (3) NPEV as the single most frequently and persistently detected infectious agent in PIFoBM-ND and (4) an association of approximately 50% of NPEV infection episodes with gastrointestinal diseases involving diarrhoea and IFoBM-ND. PD and IFoBM-ND episodes could result in high morbidity and/or mortality in rural community settings, imposing extreme trauma and economic burden on poor families in developing countries. Our recent and present findings of significant NPEV association with acute and persistent symptomatic infections involving diarrhoea and IFoBM-ND in children are of great clinical significance and child health concern, warranting urgent global attention for detailed future investigations on these ubiquitous viruses which remained neglected and unrecognised as enteric pathogens.
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